Not Yet Recruiting
A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC
NCT07562581
- Conditions
- KRAS-mutated, Metastasis, Neoplasm Metastasis, +6 more
- Locations
-
- Shanghai Chest Hospital Shanghai, Shanghai Municipality, China